The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.

Inclusion Criteria:

• Postmenopausal women with established coronary heart disease or at risk for a major coronary event.

Exclusion Criteria:

• Postmenopausal symptoms that required estrogen replacement therapy.
• Suspected or known history of breast or endometrial carcinoma.
• Known or probable history of deep venous thrombosis, pulmonary embolism, or retinal vein thrombosis.
• New York Heart Association classes III or IV heart failure.